FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200596350> ?p ?o ?g. }

• W3200596350 abstract "Objective: To assess safety and tolerability of oral ponesimod and teriflunomide in patients with relapsing multiple sclerosis (RMS) in phase 3 OPTIMUM study. Background: Ponesimod, an orally active, second-generation, rapidly reversible, highly selective sphingosine-1-phosphate receptor 1 (S1P1) modulator causes sequestration of lymphocytes in lymphoid organs, leading to reduced blood lymphocyte counts. Design/Methods: Patients (18–55 years) with RMS were randomized (1:1) to ponesimod 20 mg or teriflunomide 14 mg for 108 weeks. For ponesimod, a 14-day gradual up-titration, starting with 2-mg, was implemented to mitigate potential first-dose cardiac effects associated with S1P-receptor modulators. Safety was assessed based on incidence of treatment-emergent adverse events (TEAEs), AEs of special interest (AESIs), cardiac monitoring and laboratory results. Results: Of 1131 patients treated (ponesimod: n=565, teriflunomide: n=566), 83.1% and 83.6% patients completed treatment, respectively. Incidence of TEAEs (88.8% vs 88.2%) and serious AEs (8.7% vs 8.1%) were similar. Most common TEAEs in ponesimod vs. teriflunomide groups were increased alanine aminotransferase (ALT) levels (19.5% vs 9.4%), nasopharyngitis (19.3% vs 16.8%), headache (11.5% vs 12.7%), and upper respiratory tract infection (10.6% vs 10.4%). Two deaths were reported in the teriflunomide group. TEAEs leading to treatment discontinuation were 8.7% and 6.0% in ponesimod and teriflunomide groups. Most common AESIs up to end-of-treatment (EOT)+15 days, unless otherwise specified, were hepatobiliary disorders/liver enzyme abnormalities (EOT+1 day) (22.7% vs 12.2%), hypertension (10.1% vs 9.0%), and pulmonary events (8.0% vs 2.7%). ALT increase ≥3×upper limit of normal (ULN) was higher with ponesimod (17.3% vs 8.3%), while ALT increase ≥8×ULN was more frequent with teriflunomide (0.7% vs 2.1%) treatment. Events related to heart rate and rhythm (including hypotension) on Day 1 occurred in 2.1% of ponesimod patients and were neither serious nor led to permanent discontinuation. Conclusions: Ponesimod’s safety profile was consistent with previous safety observations of ponesimod and the known profile of other S1P receptor modulators. Disclosure: Dr. Sprenger has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with I did not receive any personal compensation. My employer received compensation for speaking, advisory board/consulting activities from: Actelion, Lilly, Roche, Novartis, Sanofi Genzyme and Teva.. Dr. Burcklen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion Pharmaceuticals, a Janssen Pharmaceutical company of Johnson & Johnson. Dr. Burcklen has received compensation for serving on the Board of Directors of Johnson & Johnson. Dr. Freedman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Bayer Healthcare, Biogen Idec, Chugai, Clene Nanomedicine, EMD Serono Canada, Genzyme, Merck Serono, Novartis, F. Hoffmann-La Roche Ltd, Sanofi-Aventis and Teva Canada Innovation. Dr. Freedman has received compensation for serving on the Board of Directors of Actelion, Bayer Healthcare, Biogen Idec, Clene Nanomedicine, F. Hoffmann-La Roche Ltd, Merck Serono, MedDay Pharmaceuticals, Novartis and Sanofi-Aventis. Dr. Freedman has received research support from Genzyme Canada. Dr. Fox has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Robert Fox has received compensation for serving as a consultant or speaker from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, and Teva. He, or the institution he works for, has received research support from Novartis.. Dr. Fox has received research support from He, or the institution he works for, has received research support from Novartis..Dr. Havrdova has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Biogen, Celgene Corporation, Merck, Novartis, Roche, Sanofi, and Teva. Dr. Havrdova has received research support from Czech Ministry of Education, project PROGRES Q27/LF1.Dr. Hennessy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion Pharmaceuticals, a Janssen Pharmaceutical company of Johnson & Johnson. Dr. Hennessy has received compensation for serving on the Board of Directors of Johnson & Johnson, Novo Nordisk, Arena Pharmaceuticals, and Galapagos. Dr. Hohlfeld has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Biogen, Genzyme-Sanofi, Novartis, and Roche. Dr. Hohlfeld has received research support from Biogen, Genzyme-Sanofi, Novartis, and Roche. Dr. Lublin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen; EMD Serono; Novartis; Teva; Actelion; Sanofi/Genzyme; Acorda; Roche/Genentech; MedImmune; Receptos/Celgene; Forward Pharma; TG Therapeutics; Abbvie; Regeneron; Medday; Atara Biotherapeutics; Polpharma; Mapi Pharma; Innate Immunotherapeutics; Apito. Dr. Lublin has received personal compensation in an editorial capacity for Multiple Sclerosis and Related Disorders- Co-Chief Editor. Dr. Lublin has received research support from Acorda Therapeutics, Biogen Idec, Genzyme, National MS Society, Novartis, Sanofi, Teva Neuroscience. Dr. Montalban has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Alexion, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Hoffmann-La Roche, Immunic AG, Medday, Medscape, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical and TG Therapeutics. Dr. Montalban has received research support from Abbvie, Biogen, Hoffmann-La Roche, Medday, Merck, Novartis, Sanofi-Genzyme and Teva Pharmaceutical.Dr. Pozzilli has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Served on scientific advisory boards for Novartis, Merck, Biogen, Sanofi, Genzyme, Teva, Actelion and funding for travel and speaker honoraria from Biogen, Teva, Sanofi Genzyme, Actelion and Novartis. Dr. Pozzilli has received research support from Biogen, Teva, Novartis and Genzyme. Dr. Vaclavkova has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Part of Janssen Pharmaceutical company of Johnson & Johnson. Dr. Vaclavkova has received compensation for serving on the Board of Directors of Johnson & Johnson. Dr. Scherz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Actelion Pharmaceuticals, a Janssen Pharmaceutical company of Johnson & Johnson and a former employee of Novartis Pharma AG. Dr. Scherz has received compensation for serving on the Board of Directors of Johnson & Johnson. Dr. Linscheid has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with employee of Actelion Pharmaceuticals, a Janssen Pharmaceutical company of Johnson & Johnson.. Dr. Pirozek-Lawniczek has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with are employee of Actelion Pharmaceuticals, a Janssen Pharmaceutical company of Johnson & Johnson.. Dr. Kracker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with employee of Actelion Pharmaceuticals, a Janssen Pharmaceutical company of Johnson & Johnson. Dr. Kappos has received research support from Bayer, Biogen, Innosuisse, Novartis, the Swiss MS Society, the Swiss National Research Foundation, and the European Union." @default.
• W3200596350 created "2021-09-27" @default.
• W3200596350 creator A5005896665 @default.
• W3200596350 creator A5010641442 @default.
• W3200596350 creator A5021092653 @default.
• W3200596350 creator A5025501697 @default.
• W3200596350 creator A5028689651 @default.
• W3200596350 creator A5029734617 @default.
• W3200596350 creator A5031171090 @default.
• W3200596350 creator A5032552975 @default.
• W3200596350 creator A5045666977 @default.
• W3200596350 creator A5046803588 @default.
• W3200596350 creator A5051313308 @default.
• W3200596350 creator A5054874316 @default.
• W3200596350 creator A5078067575 @default.
• W3200596350 creator A5080009153 @default.
• W3200596350 creator A5083385630 @default.
• W3200596350 creator A5090856144 @default.
• W3200596350 date "2020-04-14" @default.
• W3200596350 modified "2023-09-23" @default.
• W3200596350 title "Safety and Tolerability of Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study (1770)" @default.
• W3200596350 hasPublicationYear "2020" @default.
• W3200596350 type Work @default.
• W3200596350 sameAs 3200596350 @default.
• W3200596350 citedByCount "0" @default.
• W3200596350 crossrefType "journal-article" @default.
• W3200596350 hasAuthorship W3200596350A5005896665 @default.
• W3200596350 hasAuthorship W3200596350A5010641442 @default.
• W3200596350 hasAuthorship W3200596350A5021092653 @default.
• W3200596350 hasAuthorship W3200596350A5025501697 @default.
• W3200596350 hasAuthorship W3200596350A5028689651 @default.
• W3200596350 hasAuthorship W3200596350A5029734617 @default.
• W3200596350 hasAuthorship W3200596350A5031171090 @default.
• W3200596350 hasAuthorship W3200596350A5032552975 @default.
• W3200596350 hasAuthorship W3200596350A5045666977 @default.
• W3200596350 hasAuthorship W3200596350A5046803588 @default.
• W3200596350 hasAuthorship W3200596350A5051313308 @default.
• W3200596350 hasAuthorship W3200596350A5054874316 @default.
• W3200596350 hasAuthorship W3200596350A5078067575 @default.
• W3200596350 hasAuthorship W3200596350A5080009153 @default.
• W3200596350 hasAuthorship W3200596350A5083385630 @default.
• W3200596350 hasAuthorship W3200596350A5090856144 @default.
• W3200596350 hasConcept C118552586 @default.
• W3200596350 hasConcept C126322002 @default.
• W3200596350 hasConcept C142724271 @default.
• W3200596350 hasConcept C197934379 @default.
• W3200596350 hasConcept C204787440 @default.
• W3200596350 hasConcept C27081682 @default.
• W3200596350 hasConcept C2776036978 @default.
• W3200596350 hasConcept C2777703276 @default.
• W3200596350 hasConcept C2778375690 @default.
• W3200596350 hasConcept C2780640218 @default.
• W3200596350 hasConcept C2991744798 @default.
• W3200596350 hasConcept C71924100 @default.
• W3200596350 hasConceptScore W3200596350C118552586 @default.
• W3200596350 hasConceptScore W3200596350C126322002 @default.
• W3200596350 hasConceptScore W3200596350C142724271 @default.
• W3200596350 hasConceptScore W3200596350C197934379 @default.
• W3200596350 hasConceptScore W3200596350C204787440 @default.
• W3200596350 hasConceptScore W3200596350C27081682 @default.
• W3200596350 hasConceptScore W3200596350C2776036978 @default.
• W3200596350 hasConceptScore W3200596350C2777703276 @default.
• W3200596350 hasConceptScore W3200596350C2778375690 @default.
• W3200596350 hasConceptScore W3200596350C2780640218 @default.
• W3200596350 hasConceptScore W3200596350C2991744798 @default.
• W3200596350 hasConceptScore W3200596350C71924100 @default.
• W3200596350 hasLocation W32005963501 @default.
• W3200596350 hasOpenAccess W3200596350 @default.
• W3200596350 hasPrimaryLocation W32005963501 @default.
• W3200596350 hasRelatedWork W2799729405 @default.
• W3200596350 hasRelatedWork W2802289366 @default.
• W3200596350 hasRelatedWork W2809796400 @default.
• W3200596350 hasRelatedWork W2810108141 @default.
• W3200596350 hasRelatedWork W2886986327 @default.
• W3200596350 hasRelatedWork W2890304873 @default.
• W3200596350 hasRelatedWork W2951843712 @default.
• W3200596350 hasRelatedWork W3019192457 @default.
• W3200596350 hasRelatedWork W3019627920 @default.
• W3200596350 hasRelatedWork W3043124915 @default.
• W3200596350 hasRelatedWork W3093868839 @default.
• W3200596350 hasRelatedWork W3095735295 @default.
• W3200596350 hasRelatedWork W3100356785 @default.
• W3200596350 hasRelatedWork W3131226976 @default.
• W3200596350 hasRelatedWork W3160338964 @default.
• W3200596350 hasRelatedWork W3175932202 @default.
• W3200596350 hasRelatedWork W3187114413 @default.
• W3200596350 hasRelatedWork W3188387885 @default.
• W3200596350 hasRelatedWork W3193882913 @default.
• W3200596350 hasRelatedWork W3210868170 @default.
• W3200596350 hasVolume "94" @default.
• W3200596350 isParatext "false" @default.
• W3200596350 isRetracted "false" @default.
• W3200596350 magId "3200596350" @default.
• W3200596350 workType "article" @default.